Abstract
Hematologic malignancies account for a substantial percentage of cancers worldwide, and the heterogeneity and biological characteristics of leukemias and lymphomas present unique therapeutic challenges. Although treatment options exist for most of these diseases, many types remain incurable and the emergence of drug resistance is pervasive. Thus, novel treatment approaches are essential to improve outcome. Nearly half of the agents used in cancer therapy today are either natural products or derivatives of natural products. The e l,normous chemical diversity in nature, coupled with millennia of biological selection, has generated a vast and underexplored reservoir of unique chemical structures with biologic activity. This review will describe the investigation and application of natural products derived from higher plants in the treatment of leukemia and lymphoma and the rationale behind these efforts. In addition to the approved vinca alkaloids and the epipodophyllotoxin derivatives, a number of other plant compounds have shown promise in clinical trials and in preclinical investigations. In particular, we will focus on the discovery and biological evaluation of the plantderived agent silvestrol, which shows potential for additional development as a new therapeutic agent for B-cell malignancies including chronic lymphocytic leukemia.
Keywords: Epipodophylloxin derivatives, flavopiridol, hematological malignancies, leukemia, lymphoma, natural products, silvestrol, vinca alkaloids
Current Drug Targets
Title: Potential of Plant-Derived Natural Products in the Treatment of Leukemia and Lymphoma
Volume: 11 Issue: 7
Author(s): David M. Lucas, Patrick C. Still, Lynette Bueno Perez, Michael R. Grever and A. Douglas Kinghorn
Affiliation:
Keywords: Epipodophylloxin derivatives, flavopiridol, hematological malignancies, leukemia, lymphoma, natural products, silvestrol, vinca alkaloids
Abstract: Hematologic malignancies account for a substantial percentage of cancers worldwide, and the heterogeneity and biological characteristics of leukemias and lymphomas present unique therapeutic challenges. Although treatment options exist for most of these diseases, many types remain incurable and the emergence of drug resistance is pervasive. Thus, novel treatment approaches are essential to improve outcome. Nearly half of the agents used in cancer therapy today are either natural products or derivatives of natural products. The e l,normous chemical diversity in nature, coupled with millennia of biological selection, has generated a vast and underexplored reservoir of unique chemical structures with biologic activity. This review will describe the investigation and application of natural products derived from higher plants in the treatment of leukemia and lymphoma and the rationale behind these efforts. In addition to the approved vinca alkaloids and the epipodophyllotoxin derivatives, a number of other plant compounds have shown promise in clinical trials and in preclinical investigations. In particular, we will focus on the discovery and biological evaluation of the plantderived agent silvestrol, which shows potential for additional development as a new therapeutic agent for B-cell malignancies including chronic lymphocytic leukemia.
Export Options
About this article
Cite this article as:
M. Lucas David, C. Still Patrick, Bueno Perez Lynette, R. Grever Michael and Douglas Kinghorn A., Potential of Plant-Derived Natural Products in the Treatment of Leukemia and Lymphoma, Current Drug Targets 2010; 11 (7) . https://dx.doi.org/10.2174/138945010791320809
DOI https://dx.doi.org/10.2174/138945010791320809 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bench to Bedside Targeting of FLT3 in Acute Leukemia
Current Drug Targets Angiogenesis and Hemostasis in Hematological Neoplasias
Current Drug Targets Vinorelbine in the Treatment of Non-Small Cell Lung Cancer
Current Medicinal Chemistry Antiproliferative and Proapoptotic Effects of Proteasome Inhibitors and their Combination with Histone Deacetylase Inhibitors on Leukemia Cells
Cardiovascular & Hematological Disorders-Drug Targets From Conformation to Interaction: Techniques to Explore the Hsp70/ Hsp90 Network
Current Protein & Peptide Science Receptor Tyrosine Kinases as Therapeutic Targets in Malignant Glioma
Reviews on Recent Clinical Trials Hollow Inorganic Nanoparticles as Efficient Carriers for siRNA Delivery: A Comprehensive Review
Current Pharmaceutical Design Topotecan in Second-Line Treatment of Small-Cell Lung Cancer – How it Works in Our Daily Clinical Practice?
Current Drug Safety Biosafety of Adenoviral Vectors
Current Gene Therapy Iron Chelators for the Treatment of Cancer
Current Medicinal Chemistry Myeloproliferative Neoplasms Including Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis, Chronic Neutrophilic Leukemia, and Myeloproliferative Neoplasm, Unclassifiable
Current Cancer Therapy Reviews Clioquinol – A Novel Copper-Dependent and Independent Proteasome Inhibitor
Current Cancer Drug Targets Seek and Destroy: The Use of Natural Compounds for Targeting the Molecular Roots of Cancer
Current Drug Targets Potential Role of PKC Inhibitors in the Treatment of Hematological Malignancies
Current Pharmaceutical Design Patent Selections
Recent Patents on Biomedical Engineering (Discontinued) MicroRNAs and Aging: Biomarkers or Therapeutic Targets?
Current Aging Science BIBR 1532 Increases Arsenic Trioxide-mediated Apoptosis in Acute Promyelocytic Leukemia Cells: Therapeutic Potential for APL
Anti-Cancer Agents in Medicinal Chemistry Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects
Current Cancer Drug Targets Mean Platelet Volume and Platelet Distribution Width Correlate with Microvascular Complications in Egyptian People with Type 2 Diabetes Mellitus
Current Diabetes Reviews